Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Q2 2026 earnings

Reported May 15, 2026 · Before market open

Revenue$1.7MMiss by $5.3MDiluted EPS-$0.27Miss by $0.26
Revenue estimate$7.0M
EPS estimate-$0.01

Next report

Aug 18, 2026 (in a month)
Revenue estimate$5.8M
EPS estimate-$0.04

Financials

Q2 2026

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$67.07M-17.8%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Versus estimates

Revenue

Q2 2026$1.7MMiss by $5.3M
Q1 2026$3.9MMiss by $428.9K

Diluted EPS

Q2 2026-$0.27Miss by $0.26
Q1 2026-$0.06Miss by $0.02Q4 2025-$0.06In lineQ3 2025-$0.08Beat by $0.07Q1 2025-$0.11Miss by $0.02Q4 2024-$0.09Miss by $0.03

Ask the moment Citius Oncology, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Citius Oncology, Inc. report Q2 2026 earnings?
Citius Oncology, Inc. (CTOR) reported Q2 2026 earnings on May 15, 2026 before market open.
What were Citius Oncology, Inc.'s Q2 2026 revenue and EPS?
Citius Oncology, Inc. reported revenue of $1.7M and diluted EPS of $-0.27 for Q2 2026.
Did Citius Oncology, Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $7.0M by $5.3M. EPS missed the consensus estimate of $-0.01 by $0.26.
Where can I find Citius Oncology, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-057883) and the 10-Q periodic report (0001213900-26-057841) directly on SEC EDGAR. The filing index links above go to sec.gov.